PART I Business Overview International Stem Cell Corporation (sometimes referred to herein as ISCO, the Company, we, us, or our) is a clinical stage biotechnology company focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities and two revenue-generating businesses offering potential for increased future revenue. We currently have no revenue generated from our principal operations in therapeutic and clinical product development through research ...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-131723 | EDGAR | 45K words |
| 2025-03-28 | 2024-12-31 | 0000950170-25-046745 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038092 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000950170-23-010977 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001564590-22-012221 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001564590-21-016653 | EDGAR | — |
| 2020-06-01 | 2019-12-31 | 0001564590-20-027718 | EDGAR | — |
| 2019-04-15 | 2018-12-31 | 0001564590-19-011540 | EDGAR | — |
| 2018-04-09 | 2017-12-31 | 0001564590-18-007802 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001564590-17-005854 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-280090 | EDGAR | 22K words |
| 2025-08-14 | 2025-06-30 | 0001193125-25-180761 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071338 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126268 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096128 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059478 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062890 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041762 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0000950170-23-021741 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001564590-22-037618 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001564590-22-029273 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001564590-22-020039 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-11-18 | 0001683168-25-008521 | EDGAR | 1K words |
| 2025-09-16 | 0001683168-25-007018 | EDGAR | — |
| 2024-09-17 | 0001683168-24-006436 | EDGAR | — |
| 2023-09-18 | 0001683168-23-006510 | EDGAR | — |
| 2023-06-21 | 0001683168-23-004312 | EDGAR | — |
| 2023-03-16 | 0001683168-23-001546 | EDGAR | — |
| 2022-09-16 | 0001683168-22-006449 | EDGAR | — |
| 2022-06-14 | 0001683168-22-004317 | EDGAR | — |
| 2022-04-29 | 0001683168-22-003021 | EDGAR | — |
| 2022-03-03 | 0001564590-22-008509 | EDGAR | — |
280 total filings indexed. 248 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001355790 |
| Ticker | ISCO |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report